

MANAGEMENT OF METASTATIC CUTANEOUS CROHN'S DISEASE USING USTEKINUMAB: A SINGLE CENTRE STUDY

Shaji Sebastian

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A single-centre retrospective review of 10 patients with biopsy-proven metastatic Crohn's disease reports improvement in all patients treated with ustekinumab, with complete healing in 4 and partial response in 6.

KEY POINTS

- Ten patients with cutaneous Crohn's disease (median age 53 years, most commonly perianal location) were treated with ustekinumab after 90% had failed anti-TNF therapy
- All patients showed improvement with a median time to response of 10 weeks, with 4 achieving complete healing and 6 showing partial response over a median 45-month follow-up
- Dose escalation was performed in 8 patients, and most maintained therapeutic or supratherapeutic drug levels ranging from 2 to 6 mg/L
- The authors conclude that their series shows satisfactory response to ustekinumab in metastatic Crohn's disease, though larger studies are needed for confirmation

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/1a0e0c02-743d-11ee-b45c-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.